Volume 11, Issue 3 (Summer 2022)
aumj 2022, 11(3): 280-288 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Dolati S, Soltani-Zangbar M S, Etemadi Khiavi J, Mojahedi M, Danaii S, Ahmadian heris J et al . The Effect of Lymphocyte Therapy on the Expression of MicroRNAs in Women with Recurrent Pregnancy Loss. aumj 2022; 11 (3) :280-288
URL: http://aums.abzums.ac.ir/article-1-1541-en.html
URL: http://aums.abzums.ac.ir/article-1-1541-en.html
Sanam Dolati1 
, Mohammad Sadegh Soltani-Zangbar2 , Jalal Etemadi Khiavi3 , Maryam Mojahedi2 , Shahla Danaii4 , Javad Ahmadian heris *2 , Mehdi Yousefi2
, Mohammad Sadegh Soltani-Zangbar2 , Jalal Etemadi Khiavi3 , Maryam Mojahedi2 , Shahla Danaii4 , Javad Ahmadian heris *2 , Mehdi Yousefi2
1- Physical Medicine and Rehabilitation Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran
2- Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3- Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
4- Gynecology Department, Eastern Azerbaijan ACECR ART Center, Eastern Azerbaijan Branch of ACECR, Tabriz, Iran
2- Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3- Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
4- Gynecology Department, Eastern Azerbaijan ACECR ART Center, Eastern Azerbaijan Branch of ACECR, Tabriz, Iran
Abstract: (2877 Views)
Background: Recurrent Pregnancy Loss (RPL) is 2 or more recurrent miscarriages before the twentieth week, which occurs in 2-5% of women of gestational age. Considering the significant role of the immune system in the process of a successful pregnancy, it is expected that in addition to the common and well-known treatments used for patients with recurrent miscarriage to date, intracutaneous lymphocyte therapy will also be effective.
Methods: 30 patients with RPL with immunological disorders, and 30 patients in a control group consisting of healthy women with a history of successful pregnancies were included in the study. After receiving blood samples and initial examinations, people with RPL received lymphocytic treatment. Before and after the intervention, the expression levels of miR-146a, miR-10a, miR-106b, and miR-25 were measured in both groups and the differences caused by the effects of this intervention were examined.
Results: The expression of anti-inflammatory miR-146a and miR-10a, in women with RPL showed a significant increase after receiving lymphocyte treatment compared to before treatment. While the expression of pro-inflammatory miR-106b and miR-25 showed a significant decrease after receiving lymphocytes compared to before treatment.
Conclusion: The aim of intradermal lymphocyte therapy is to increase the maternal immune system's tolerance to paternal antigens in the fetus and to modulate inflammatory responses in pregnant women with RPL. According to the results of this study, this method can be used to reduce inflammation in women with recurrent miscarriage.
Methods: 30 patients with RPL with immunological disorders, and 30 patients in a control group consisting of healthy women with a history of successful pregnancies were included in the study. After receiving blood samples and initial examinations, people with RPL received lymphocytic treatment. Before and after the intervention, the expression levels of miR-146a, miR-10a, miR-106b, and miR-25 were measured in both groups and the differences caused by the effects of this intervention were examined.
Results: The expression of anti-inflammatory miR-146a and miR-10a, in women with RPL showed a significant increase after receiving lymphocyte treatment compared to before treatment. While the expression of pro-inflammatory miR-106b and miR-25 showed a significant decrease after receiving lymphocytes compared to before treatment.
Conclusion: The aim of intradermal lymphocyte therapy is to increase the maternal immune system's tolerance to paternal antigens in the fetus and to modulate inflammatory responses in pregnant women with RPL. According to the results of this study, this method can be used to reduce inflammation in women with recurrent miscarriage.
Type of Study: Research |
Subject:
Special
Received: 2022/05/10 | Accepted: 2022/07/01 | Published: 2022/07/01
Received: 2022/05/10 | Accepted: 2022/07/01 | Published: 2022/07/01
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
